Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122272403 | 12227240 | 3 | F | 20160307 | 20160728 | 20160331 | 20160805 | EXP | BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-19186BI | BOEHRINGER INGELHEIM | 63.66 | YR | M | Y | 103.30000 | KG | 20160805 | MD | COUNTRY NOT SPECIFIED | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122272403 | 12227240 | 1 | PS | LINAGLIPTIN | LINAGLIPTIN | 1 | Oral | 5 MG | 201280 | 5 | MG | TABLET | QD | ||||||
| 122272403 | 12227240 | 2 | SS | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | Oral | 25 MG | Y | 0 | 25 | MG | QD | ||||||
| 122272403 | 12227240 | 3 | SS | ENALAPRIL | ENALAPRIL | 1 | Oral | 40 MG | Y | 0 | 40 | MG | QD | ||||||
| 122272403 | 12227240 | 4 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 2550 MG | 0 | 2550 | MG | QD | |||||||
| 122272403 | 12227240 | 5 | C | GLICLAZIDE | GLICLAZIDE | 1 | Oral | 90 MG | 0 | 90 | MG | QD | |||||||
| 122272403 | 12227240 | 6 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 100 MG | 0 | 100 | MG | QD | |||||||
| 122272403 | 12227240 | 7 | C | CARVEDILOL. | CARVEDILOL | 1 | Oral | 37.5 MG | 0 | 37.5 | MG | QD | |||||||
| 122272403 | 12227240 | 8 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 40 MG | 0 | 40 | MG | QD | |||||||
| 122272403 | 12227240 | 9 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 20 MG | 0 | 20 | MG | QD | |||||||
| 122272403 | 12227240 | 10 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 20 MG | 0 | 20 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122272403 | 12227240 | 1 | Type 2 diabetes mellitus |
| 122272403 | 12227240 | 2 | Cardiac failure congestive |
| 122272403 | 12227240 | 3 | Hypertension |
| 122272403 | 12227240 | 4 | Diabetes mellitus |
| 122272403 | 12227240 | 5 | Diabetes mellitus |
| 122272403 | 12227240 | 6 | Myocardial infarction |
| 122272403 | 12227240 | 7 | Cardiac failure congestive |
| 122272403 | 12227240 | 8 | Cardiac failure congestive |
| 122272403 | 12227240 | 10 | Dyslipidaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122272403 | 12227240 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122272403 | 12227240 | Acute kidney injury | |
| 122272403 | 12227240 | Hyperkalaemia | |
| 122272403 | 12227240 | Upper respiratory tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122272403 | 12227240 | 1 | 20151008 | 0 | ||
| 122272403 | 12227240 | 2 | 20150805 | 20160316 | 0 | |
| 122272403 | 12227240 | 3 | 201402 | 20160316 | 0 | |
| 122272403 | 12227240 | 4 | 2013 | 0 | ||
| 122272403 | 12227240 | 5 | 2014 | 0 | ||
| 122272403 | 12227240 | 6 | 2002 | 0 | ||
| 122272403 | 12227240 | 7 | 20150805 | 0 | ||
| 122272403 | 12227240 | 8 | 201402 | 20151216 | 0 | |
| 122272403 | 12227240 | 9 | 20151217 | 20160316 | 0 | |
| 122272403 | 12227240 | 10 | 2002 | 0 |